Expression analysis of CBR3-AS1 and androgen receptor genes in breast cancer

Publication date: September 2018 Source:Meta Gene, Volume 17 Author(s): Sepideh Faramarzi, Ali Dianatpour, Lobat Geranpayeh, Reza Mirfakhraie, Roshanak Shams, Mahnaz Seifi-Alan, Vahid Kholghi Oskoei, Soudeh Ghafouri-Fard Long non-coding RNAs (lncRNAs) have been shown to participate in the pathogenesis of a variety of cancers including breast cancer. The lncRNA Carbonyl reductase 3-Antisense 1 (CBR3-AS1) has been implicated in some human malignancies in association with androgen receptor (AR). In the present study, we evaluated the expression of CBR3-AS1 and AR transcripts in 52 breast cancer tissues, their corresponding adjacent non-cancerous tissues (ANCTs) and two breast cancer cell lines (MDA-MB-231 and MCF-7). We extracted data of our previously published work regarding expression level of Zinc-finger enhancer binding protein (ZEB1) in the same cohort of patients. CBR3-AS1 was up-regulated in MDA-MB-231 compared with ANCTs. AR was significantly down-regulated in both breast cancer cell lines compared with ANCTs. AR expression was lower in tumoral tissues compared with ANCTs but it did not reach the level of significance. CBR3-AS1 expression has been shown to be significantly elevated in tumor tissues compared with ANCTs (fold change = 4.178, P = 0.021). No significant associations have been detected between the level of transcripts and patients' data except for an association between AR expression and cancer stage (P = 0.037). In luminal B subtype, A...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research